Karyopharm
Newton, Massachusetts, United States
Sharon Tamir
Sr. Director, Head of Neuro-Oncology and Infectious Diseases
Karyopharm Therapeutics Inc
Currently, as the Head of the Neuro-Oncology and Infectious Diseases at Karyopharm, I am focused on the development of Selinexor, also known as KPT-330, selective inhibitor of nuclear export compound, for the treatment of patients with Glioblastoma and other neuro-oncology indications, along with several viral diseases.
